CN104740130A - Pharmaceutical composition for treating chronic nephritis - Google Patents
Pharmaceutical composition for treating chronic nephritis Download PDFInfo
- Publication number
- CN104740130A CN104740130A CN201510205425.0A CN201510205425A CN104740130A CN 104740130 A CN104740130 A CN 104740130A CN 201510205425 A CN201510205425 A CN 201510205425A CN 104740130 A CN104740130 A CN 104740130A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- treatment
- chronic nephritis
- radix
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention belongs to the mechanical technical field and in particular relates to a pharmaceutical composition for treating chronic nephritis. The pharmaceutical composition is prepared from components of rhizoma curculiginis, stephania tetrandra, red ginseng, red flower, myrrh, herba lycopi, seed of Chinese dodder, fructus schizandrae, achyranthes bidentata, radix angelicae dahuricae and the like. The pharmaceutical composition disclosed by the invention is exact in curative effect of treating chronic nephritis, high in safety, and can be used as a first-choice drug for treating chronic nephritis.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind of pharmaceutical composition for the treatment of chronic nephritis.
Background technology
Chronic nephritis is a kind of common disease being cardinal symptom with hematuria, edema, albuminuria and hypertension, and this disease is attended by renal failure more, disease slowly, the longer and Relapse rate of the course of disease.Major part patient fall ill time first show edema or (and) albuminuria, small part patient is only had only to show the two micro-serious symptom shape of lower limb of face, some patients is also had to take nephrotic syndrome as main manifestations, the treatment of current chronic nephritis is based on western medical treatment, but clinical therapeutic efficacy is not very good.
This disease is belonged to the category such as " asthenia ", " edema ", " hematuria ", " lumbago " by the traditional Chinese medical science, in conjunction with the pattern of syndrome symptomatic treatment that they are different, produces effects excellent.Chinese medicine treatment chronic nephritis has very abundant historical experience, defines unique theoretical system.And Chinese medicine safety range is large, toxic and side effects is little, and effect link is more, successful, simultaneously cheap, is easy to preparation, curative effect is direct, be worth carrying out more deep research and development.
Summary of the invention
The invention provides a kind of pharmaceutical composition for the treatment of chronic nephritis, its determined curative effect, safety is high, can be used as the desirable preparation for the treatment of chronic nephritis.Pharmaceutical composition prescription of the present invention is rigorous, and compatibility science is evident in efficacy, easy to prepare, and patient compliance is good, without any side effects, clinic promotion and application.
For achieving the above object, technical scheme provided by the invention is the pharmaceutical composition of described treatment chronic nephritis, is made up of the medicine of following weight proportion: Rhizoma Curculiginis 7-9g, Radix Stephaniae Tetrandrae 8-10g, Radix Ginseng Rubra 5-8g, Flos Carthami 7-9g, Myrrha 12-18g, Herba Lycopi 8-12g, Semen Cuscutae 6-10g, Fructus Schisandrae Chinensis 15-18g, Radix Achyranthis Bidentatae 13-16g, Radix Angelicae Dahuricae 8-12g.
Most preferred technique scheme of the present invention is that pharmaceutical composition of the present invention is obtained by the material medicine of following weight proportion: Rhizoma Curculiginis 8g, Radix Stephaniae Tetrandrae 9g, Radix Ginseng Rubra 6g, Flos Carthami 8g, Myrrha 15g, Herba Lycopi 10g, Semen Cuscutae 8g, Fructus Schisandrae Chinensis 16g, Radix Achyranthis Bidentatae 15g, Radix Angelicae Dahuricae 10g.
Present invention also offers the preparation method of described pharmaceutical composition, specifically comprise: take above Chinese medicine component according to aforesaid weight and be ground into coarse powder respectively, decoct 2 times, add the water of medicine gross weight 8 times at every turn, decoct 2 hours, merge decoction liquor, filter; Filtrate reduced in volume becomes extractum, adding ethanol to alcohol content is 75%v/v, leave standstill 12 hours, get supernatant, reclaim ethanol to concentrated, cold drying, the traditional Chinese medicine fine powder of pulverizing, add proper auxiliary materials, eventually pass normal process steps and add pharmaceutically acceptable excipients and make clinical acceptable dosage form.
Pharmaceutical composition of the present invention can be prepared into oral formulations.Preferably be prepared into capsule or tablet.
When above-mentioned oral formulations is capsule, its prescription is:
The preparation method of described capsule, has the following steps: be dissolved in 0.4% ammonia spirit of 75% (V/V) ethanol by beta-schardinger dextrin-, traditional Chinese medicine fine powder, preparation temperature 50 C; The mixed liquor spray drying method of gained is carried out drying, and wherein spray drying parameters is: inlet temperature 50 DEG C, spray velocity 2ml/min, and atomisation pressure is 5bar, finally collects dried cyclodextrin clathrate; Take cyclodextrin clathrate, cellulose acetate-phthalate, polyvinylpolypyrrolidone join in appropriate 75% (V/V) ethanol, stirring and dissolving at 50 DEG C; Insulation, rotary evaporation, prepares solid dispersion; Prepared solid dispersion is dry, sieve, then mix with the microcrystalline Cellulose of recipe quantity, magnesium stearate, in incapsulating, obtain capsule.
The present invention, relative to prior art, has following clear superiority:
First, pharmaceutical composition prescription of the present invention mainly develops according to the pathogenic characteristic of patients with chronic glomerulonephritis, Rhizoma Curculiginis, Radix Achyranthis Bidentatae, Semen Cuscutae kidney-replenishing, bone and muscle strengthening in side; Radix Stephaniae Tetrandrae, Herba Lycopi, Flos Carthami promoting blood circulation to remove obstruction in the collateral, inducing diuresis to remove edema, wind-expelling pain-stopping; Astringent or styptic treatment for spontaneous sweating, the supplementing QI for promoting the production of body fluid of Fructus Schisandrae Chinensis convergence, kidney calming; The dehumidifying of the Radix Angelicae Dahuricae, Myrrha dissipating blood stasis, wind-expelling pain-stopping; The multiple arteries and veins of Radix Ginseng Rubra is admittedly de-, nourishing qi to stop.This pharmaceutically dosage form is advanced, and preparation is simple, is suitable for large technological process to be produced, and determined curative effect, easy to use, have no side effect.In prescription, all medicines share the effect with kidney-replenishing, bone and muscle strengthening, promoting blood circulation to remove obstruction in the collateral, inducing diuresis to remove edema, have extremely strong specific aim curative effect to chronic nephritis.Through clinical practice checking, its determined curative effect, mild in medicine property and, do not occur toxic and side effects and untoward reaction, safety coefficient is high.
Further, in pharmaceutical composition of the present invention, the function of each crude drug cures mainly:
Rhizoma Curculiginis, pungent, heat; Poisonous.Return kidney,liver,spleen warp.Kidney-replenishing, bone and muscle strengthening, dispelling cold and dampness.For sexual impotence cold sperm, muscles and bones flaccidity is soft, the cold numbness of waist knee joint, yang deficiency cold diarrhea.
Radix Stephaniae Tetrandrae is bitter, cold.Return bladder, lung meridian.Inducing diuresis to remove edema, wind-expelling pain-stopping.For edema beriberi, dysuria, eczema sore, rheumatic arthralgia; Hypertension.
Radix Ginseng Rubra, sweet, micro-hardship, temperature.Return spleen, lung, heart channel.Strongly invigorating primordial QI, multiple arteries and veins takes off admittedly, nourishing qi to stop.For weak body and prostration, cold extremities faint pulse, QI failing to control blood, metrostaxis; Heart failure, cardiogenic shock.
Flos Carthami, pungent, temperature.GUIXIN, Liver Channel.Promoting blood circulation to restore menstrual flow, eliminating stasis to stop pain.For amenorrhea, dysmenorrhea, lochia ， mass in the abdomen mass in the abdomen, injury from falling down, skin infection swells and ache.
Myrrha is bitter, flat.Eliminating stasis to stop pain, externally used detumescence granulation promoting.Swell and ache for traumatic injury congestion, ulcer sore pain, all pains of breast abdomen; External is controlled the open sore part and is not restrained for a long time.
Herba Lycopi, bitter, pungent, tepor.Return liver, spleen channel.Blood circulation promoting and blood stasis dispelling, line water detumescence.For menoxenia, amenorrhea, dysmenorrhea, postnatal blood stasis is suffered from abdominal pain, edema.
Semen Cuscutae, sweet, temperature.Return liver,kidney,spleen warp.Nourishing the liver and kidney, controlling nocturnal emission with astringent drugs reducing urination, antiabortive, improving eyesight, antidiarrheal.For impotence and seminal emission, dripping urination, enuresis frequent micturition, soreness of the waist and knees, blurred vision tinnitus, vaginal bleeding due to deficiency of the kidney during pregnancy, frequent fetal movement, spleen is suffered from a deficiency of the kidney and is rushed down; Externally treating leucoderma.
Fructus Schisandrae Chinensis, sour, sweet, temperature.Return lung, the heart, kidney channel.Restrain astringent or styptic treatment for spontaneous sweating, supplementing QI for promoting the production of body fluid, kidney calming.For chronic cough dyspnea due to deficiency, emission, enuresis frequent micturition, incessant chronic diarrhea, spontaneous perspiration, night sweat, Tianjin wound is thirsty, and deficient pulse of losing heart, interior-heat is quenched one's thirst, palpitation and insomnia.
Radix Achyranthis Bidentatae is bitter, sour, flat.Return liver, kidney channel.Invigorating the liver and kidney, bone and muscle strengthening, eliminating blood stasis and inducing menstruation, conducting blood to flow downwards.For soreness of waist and knee joint, muscles and bones is unable, amenorrhea and mass in the abdomen, dizziness due to hyperactivity of liver-YANG.
The Radix Angelicae Dahuricae, pungent, temperature.Return stomach, large intestine, lung meridian.Loose wind dehumidifying, understand things pain-stopping, detumescence and apocenosis.For headache due to common cold, supraorbital bone pain, nasal obstruction, nasal sinusitis, toothache, leucorrhea, skin infection swells and ache.
The present invention also asks the purposes protecting aforementioned pharmaceutical compositions in the medicine of preparation treatment chronic nephritis.In clinical observation process, treatment group and matched group is divided into treat at random 80 routine patients with chronic glomerulonephritis, after treatment group uses two courses for the treatment of of Drug therapy of the present invention, clinical effectiveness shows, after treatment group chronic renal inflammation patient treatment, symptom can significantly improve.And body weight, heart rate, blood pressure are showed no obvious change before and after treatment group treatment.Treatment group does not find the obvious adverse events such as irritated in whole therapeutic process.Result shows that the clinical application of we is safely and effectively, is worth studying and applying further.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but the present invention is not limited only to following specific embodiment.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, and be included within the scope of the present invention.
Embodiment 1 capsule
The each raw material of the present invention is taken: Rhizoma Curculiginis 8g, Radix Stephaniae Tetrandrae 9g, Radix Ginseng Rubra 6g, Flos Carthami 8g, Myrrha 15g, Herba Lycopi 10g, Semen Cuscutae 8g, Fructus Schisandrae Chinensis 16g, Radix Achyranthis Bidentatae 15g, Radix Angelicae Dahuricae 10g by following weight proportion.
Preparation technology is as follows:
Take above Chinese medicine component according to aforesaid weight and be ground into coarse powder respectively, decoct 2 times, the water of each medicine gross weight 8 times, decoct 2 hours, merge decoction liquor, filter; Filtrate reduced in volume becomes extractum, and adding ethanol to alcohol content is 75v/v, leaves standstill 12 hours, gets supernatant, reclaims ethanol to concentrated, cold drying, the traditional Chinese medicine fine powder of pulverizing, for subsequent use.
Beta-schardinger dextrin-100g, traditional Chinese medicine fine powder 80g are dissolved in 0.4% ammonia spirit of 75% (V/V) ethanol, preparation temperature 50 C; The mixed liquor spray drying method of gained is carried out drying, and wherein spray drying parameters is: inlet temperature 50 DEG C, spray velocity 2ml/min, and atomisation pressure is 5bar, finally collects dried cyclodextrin clathrate; Cyclodextrin clathrate, cellulose acetate-phthalate 150g, polyvinylpolypyrrolidone 70g are joined in appropriate 75% (V/V) ethanol, stirring and dissolving at 50 DEG C; Insulation, rotary evaporation, prepares solid dispersion; Prepared solid dispersion is dry, sieve, then mix with microcrystalline Cellulose 100g, the magnesium stearate 2g of recipe quantity, in incapsulating, obtain capsule 1000.
When using medicine composite for curing chronic nephritis of the present invention, use prepared tablet, each 2-3 sheet, every day 2-3 time.
Embodiment 2 capsule
The each raw material of the present invention is taken: Rhizoma Curculiginis 8g, Radix Stephaniae Tetrandrae 9g, Radix Ginseng Rubra 6g, Flos Carthami 8g, Myrrha 15g, Herba Lycopi 10g, Semen Cuscutae 8g, Fructus Schisandrae Chinensis 16g, Radix Achyranthis Bidentatae 15g, Radix Angelicae Dahuricae 10g by following weight proportion.
Preparation technology is as follows:
Take above Chinese medicine component according to aforesaid weight and be ground into coarse powder respectively, decoct 2 times, add the water of medicine gross weight 8 times at every turn, decoct 2 hours, merge decoction liquor, filter; Filtrate reduced in volume becomes extractum, and adding ethanol to alcohol content is 75%v/v, leaves standstill 12 hours, gets supernatant, reclaims ethanol to concentrated, cold drying, the traditional Chinese medicine fine powder of pulverizing, for subsequent use.
Beta-schardinger dextrin-120g, traditional Chinese medicine fine powder 100g are dissolved in 0.4% ammonia spirit of 75% (V/V) ethanol, preparation temperature 50 C; The mixed liquor spray drying method of gained is carried out drying, and wherein spray drying parameters is: inlet temperature 50 DEG C, spray velocity 2ml/min, and atomisation pressure is 5bar, finally collects dried cyclodextrin clathrate; Cyclodextrin clathrate, cellulose acetate-phthalate 180g, polyvinylpolypyrrolidone 80g are joined in appropriate 75% (V/V) ethanol, stirring and dissolving at 50 DEG C; Insulation, rotary evaporation, prepares solid dispersion; Prepared solid dispersion is dry, sieve, then mix with microcrystalline Cellulose 180g, the magnesium stearate 3g of recipe quantity, in incapsulating, obtain capsule 1000.
Embodiment 3 capsule
The each raw material of the present invention is taken: Rhizoma Curculiginis 8g, Radix Stephaniae Tetrandrae 9g, Radix Ginseng Rubra 6g, Flos Carthami 8g, Myrrha 15g, Herba Lycopi 10g, Semen Cuscutae 8g, Fructus Schisandrae Chinensis 16g, Radix Achyranthis Bidentatae 15g, Radix Angelicae Dahuricae 10g by following weight proportion.
Preparation technology is as follows:
Take above Chinese medicine component according to aforesaid weight and be ground into coarse powder respectively, decoct 2 times, add the water of medicine gross weight 8 times at every turn, decoct 2 hours, merge decoction liquor, filter; Filtrate reduced in volume becomes extractum, and adding ethanol to alcohol content is 75%v/v, leaves standstill 12 hours, gets supernatant, reclaims ethanol to concentrated, cold drying, the traditional Chinese medicine fine powder of pulverizing, for subsequent use.
Beta-schardinger dextrin-80g, traditional Chinese medicine fine powder 60g are dissolved in 0.4% ammonia spirit of 75% (V/V) ethanol, preparation temperature 50 C; The mixed liquor spray drying method of gained is carried out drying, and wherein spray drying parameters is: inlet temperature 50 DEG C, spray velocity 2ml/min, and atomisation pressure is 5bar, finally collects dried cyclodextrin clathrate; Cyclodextrin clathrate, cellulose acetate-phthalate 120g, polyvinylpolypyrrolidone 60g are joined in appropriate 75% (V/V) ethanol, stirring and dissolving at 50 DEG C; Insulation, rotary evaporation, prepares solid dispersion; Prepared solid dispersion is dry, sieve, then mix with microcrystalline Cellulose 120g, the magnesium stearate 1g of recipe quantity, in incapsulating, obtain capsule 1000.
Embodiment 4
The each raw material of the present invention is taken: Rhizoma Curculiginis 7g, Radix Stephaniae Tetrandrae 8g, Radix Ginseng Rubra 5g, Flos Carthami 7g, Myrrha 12g, Herba Lycopi 8g, Semen Cuscutae 6g, Fructus Schisandrae Chinensis 15g, Radix Achyranthis Bidentatae 13g, Radix Angelicae Dahuricae 8g by following weight proportion.
Preparation technology is with embodiment 1.
Embodiment 5
The each raw material of the present invention is taken: Rhizoma Curculiginis 9g, Radix Stephaniae Tetrandrae 10g, Radix Ginseng Rubra 8g, Flos Carthami 9g, Myrrha 18g, Herba Lycopi 12g, Semen Cuscutae 10g, Fructus Schisandrae Chinensis 18g, Radix Achyranthis Bidentatae 16g, Radix Angelicae Dahuricae 12g by following weight proportion.
Preparation technology is with embodiment 1.
The clinical observation of embodiment 6 medicine composite for curing chronic nephritis of the present invention
1, case-data: select hospital outpatient patients with chronic glomerulonephritis 80 example, adopts parallel control method to be divided into treatment group and matched group, often organizes 40 examples.Treatment group male 19 example, women 21 example, what the age was minimum is 18 years old, and maximum is 70 years old, and the mean age is 45.5 ± 3.3 years old, the course of disease 6 months-7 years, average course of disease 3.8 ± 2.3 years.Matched group male 20 example, women 20 example, what the age was minimum is 19 years old, and maximum is 71 years old, and the mean age is 44.7 years old, the course of disease 10 months-8 years, average course of disease 3.2 ± 2.1 years.The data information of two groups utilizes statistical method analyzing and processing to show without significant difference (P > 0.05), has comparability.
2, tcm diagnosis standard:
The standard that Western medicine diagnose standard chronic glomerulonephritis is drafted with reference to the peaceful meeting in June, 1992 Anhui, " primary glomerulopathy typing and treatment and diagnostic criteria symposium summary " [CHINESE JOURNAL OF INTERNAL MEDICINE, 1993, (32): 131].
Differential diagnosis in tcm (" the chronic primary glomerulus diseases Syndrome Differentiation of Traditional Chinese Medicine tentative program " that pass through with reference to the 2nd national Chinese Medical Nephrosis Symposium in 1986 and the 12nd national Chinese Medical Nephrosis academic discussion (Wuxi meeting) seminar original text revision in 1996.)
Disease: syndrome of yin deficiency of liver and kidney: primary symptom: dryness with foreign body sensation in the eyes or blurred vision, dizziness and tinnitus, dysphoria with feverish sensation in the chest palms and soles or feverish sensation in the palms and soles or dry mouth and throat, psoas muscle is ached; Secondary disease: seminal emission, spermatorrhea, or menoxenia, the few tongue of red tongue, stringy and thready pulse or count accurately.
Standard card: syndrome of blood stasis (allly possesses any one person following, can determine.) 1) complexion is dark or dark and gloomy; 2) lumbago is fixed or is twinge; 3) squamous and dry skin or numb limbs and tense tendons; 4) colour of the tongue is purple dark or have petechia, ecchymosis; 5) pulse condition is carefully puckery; 6) Urine-FDP (FOP) content raises; 7) hemorheology detects whole blood viscosity, plasma viscosity raises.
3, Therapeutic Method
Primary Care: first anti symptom treatment two groups of patients, in case aggravation.1) diet: for the patient with hypertension or edema, should be it and provides less salt food, and the Sal of absorption should control at 2 ~ 3g/d; 2) for the obvious patient of edema, should be it and diuretic is provided, to help patient to urinate fast; For the patient that hypertension is serious, should be it provides calcium ion antagonist oral; 3) patient is helped to correct electrolyte balance, anticoagulant, blood fat reducing.
Treatment group: use capsule prepared by embodiment 1, each 2-3 grain, every day 2-3 time.8w is 1 course for the treatment of.
Matched group: take shenyankangfu tablet (accurate word Z10940034, the 0.48g/ sheet of traditional Chinese medicines), a point 3 times/d takes, and warm water takes, 5 pieces/times.8w is 1 course for the treatment of.
The evaluation of clinical efficacy is carried out in continuous treatment after 1 course for the treatment of.
4, the standard of curative effect evaluation:
1) complete incidence graph: the symptoms such as edema and sign disappear completely, urine protein examination continues negative or " ± " more than 2 months.Or 24h urine protein quantitation continues < 0.2g, under high power lens, urine erythrocyte disappears, and Urine sediments analyzer counting is normal, normal renal function.
2) substantially alleviate: the symptoms such as edema and sign disappear substantially, urine protein examination continues to reduce > 50%, urine erythrocyte≤3 under high power lens, and Urine sediments analyzer counting is close normal, normal renal function or normal.
3) effective: the symptoms such as edema and sign are clearly better, and urine protein examination continues minimizing 1 "+"; Or 24h urine protein quantitation continues to reduce 25%-49%.Urine erythrocyte≤5 under high power lens, normal renal function or be improved.
4) invalid: clinical manifestation and above-mentioned lab testing are all not improved or repeatedly add severe one.
5, therapeutic effect:
In clinical observation process, 80 routine patients all complete clinical observation.Two groups of clinical effectiveness compare, treatment group clinical recovery rate 22.5%, effective percentage 92.5%, and clinical effectiveness is remarkable; Matched group clinical recovery rate 10%, effective percentage 62.5%.Two groups of therapeutic outcomes compare, and treatment group is significantly better than matched group, and especially treatment group clinical effectiveness in cure rate aspect is more remarkable.Concrete outcome is in table 1.
A table 1. liang group clinical effectiveness compares
| Group | Complete incidence graph | Basic alleviation | Effectively | Invalid | Effective percentage |
| Treatment group | 9 | 18 | 10 | 3 | 92.5％ |
| Matched group | 4 | 12 | 9 | 15 | 62.5％ |
The above results shows, after the medicine composite for curing of chronic renal inflammatory patients the application of the invention, symptom can significantly improve.In addition, rear body weight, heart rate, blood pressure are showed no obvious change to treatment group before the treatment.Treatment group does not find the obvious adverse events such as irritated in whole therapeutic process.Thus medicine composite for curing chronic nephritis determined curative effect of the present invention is described, safety is high, can be used as the medicine of chronic nephritis first-selection.
Claims (8)
1. treat the pharmaceutical composition of chronic nephritis for one kind, it is characterized in that, the composition and ratio of its primary raw material medicine is: Rhizoma Curculiginis 7-9g, Radix Stephaniae Tetrandrae 8-10g, Radix Ginseng Rubra 5-8g, Flos Carthami 7-9g, Myrrha 12-18g, Herba Lycopi 8-12g, Semen Cuscutae 6-10g, Fructus Schisandrae Chinensis 15-18g, Radix Achyranthis Bidentatae 13-16g, Radix Angelicae Dahuricae 8-12g.
2. a kind of pharmaceutical composition for the treatment of chronic nephritis as claimed in claim 1, it is characterized in that, the composition and ratio of its primary raw material medicine is: Rhizoma Curculiginis 8g, Radix Stephaniae Tetrandrae 9g, Radix Ginseng Rubra 6g, Flos Carthami 8g, Myrrha 15g, Herba Lycopi 10g, Semen Cuscutae 8g, Fructus Schisandrae Chinensis 16g, Radix Achyranthis Bidentatae 15g, Radix Angelicae Dahuricae 10g.
3. a kind of pharmaceutical composition for the treatment of chronic nephritis as described in claim 1,2, it is characterized in that, the preparation method of described pharmaceutical composition comprises following steps: take above Chinese medicine component according to aforesaid weight and be ground into coarse powder respectively, decoct 2 times, add the water of medicine gross weight 8 times at every turn, decoct 2 hours, merge decoction liquor, filter; Filtrate reduced in volume becomes extractum, adding ethanol to alcohol content is 75%v/v, leave standstill 12 hours, get supernatant, reclaim ethanol to concentrated, cold drying, is ground into traditional Chinese medicine fine powder, add proper auxiliary materials, eventually pass normal process steps and add pharmaceutically acceptable excipients and make clinical acceptable dosage form.
4. a kind of pharmaceutical composition for the treatment of chronic nephritis as claimed in claim 3, it is characterized in that, described pharmaceutical composition can be made into oral formulations.
5. a kind of pharmaceutical composition for the treatment of chronic nephritis as claimed in claim 4, it is characterized in that, described oral formulations is capsule or tablet.
6. a kind of pharmaceutical preparation for the treatment of cervical spondylosis as claimed in claim 5, is characterized in that, described capsule prescription is:
7. a kind of pharmaceutical preparation for the treatment of cervical spondylosis as claimed in claim 6, it is characterized in that, the preparation method of described capsule comprises following steps: be dissolved in 0.4% ammonia spirit of 75% ethanol by beta-schardinger dextrin-, traditional Chinese medicine fine powder, preparation temperature 50 C; The mixed liquor spray drying method of gained is carried out drying, and wherein spray drying parameters is: inlet temperature 50 DEG C, spray velocity 2ml/min, and atomisation pressure is 5bar, finally collects dried cyclodextrin clathrate; Take the cyclodextrin clathrate of recipe quantity, cellulose acetate-phthalate, polyvinylpolypyrrolidone join in appropriate 75% ethanol, stirring and dissolving at 50 DEG C; Insulation, rotary evaporation, prepares solid dispersion; Prepared solid dispersion is dry, sieve, then mix with the microcrystalline Cellulose of recipe quantity, magnesium stearate, in incapsulating, obtain capsule.
8. the purposes of the medicine as described in claim 1,2 in the pharmaceutical composition of preparation treatment chronic nephritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510205425.0A CN104740130A (en) | 2015-04-25 | 2015-04-25 | Pharmaceutical composition for treating chronic nephritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510205425.0A CN104740130A (en) | 2015-04-25 | 2015-04-25 | Pharmaceutical composition for treating chronic nephritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104740130A true CN104740130A (en) | 2015-07-01 |
Family
ID=53580752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510205425.0A Pending CN104740130A (en) | 2015-04-25 | 2015-04-25 | Pharmaceutical composition for treating chronic nephritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104740130A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239564A (en) * | 2013-05-25 | 2013-08-14 | 广州市云桥生物科技有限公司 | Chinese medicine effective part composition for treating chronic nephritis and preparation method of Chinese medicine effective part composition |
| CN103251728A (en) * | 2012-02-15 | 2013-08-21 | 王亿平 | Red ginseng-prepared rehmannia root particles for treating chronic nephritis and preparation method thereof |
| CN103948754A (en) * | 2014-05-15 | 2014-07-30 | 南京市中医院 | Drug for treating renal-deficiency humid-heat type chronic nephritis |
-
2015
- 2015-04-25 CN CN201510205425.0A patent/CN104740130A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251728A (en) * | 2012-02-15 | 2013-08-21 | 王亿平 | Red ginseng-prepared rehmannia root particles for treating chronic nephritis and preparation method thereof |
| CN103239564A (en) * | 2013-05-25 | 2013-08-14 | 广州市云桥生物科技有限公司 | Chinese medicine effective part composition for treating chronic nephritis and preparation method of Chinese medicine effective part composition |
| CN103948754A (en) * | 2014-05-15 | 2014-07-30 | 南京市中医院 | Drug for treating renal-deficiency humid-heat type chronic nephritis |
Non-Patent Citations (1)
| Title |
|---|
| 梁冰 等: "《内科病最新中医临床经验集要》", 31 October 2001 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104225441A (en) | Traditional Chinese medicine composition for treating stomach trouble and preparation method of granules and capsules of traditional Chinese medicine composition | |
| CN102362950A (en) | Traditional Chinese medicine for treating leucoderma | |
| CN106267120A (en) | A kind of Chinese medicine for treating rhinitis preparation and preparation method thereof | |
| CN104826036A (en) | Composite traditional Chinese medicine composition for treating hyperplasia of mammary glands and method for manufacturing composite traditional Chinese medicine composition | |
| CN104524071A (en) | Pharmaceutical composition for treating primary renal disease and application thereof | |
| CN103251865A (en) | Traditional Chinese medicine composite for treating diarrhea | |
| CN102430097A (en) | Chinese medicine for treating vitiligo | |
| CN104524477A (en) | Traditional Chinese medicine composition for treating nodular goiter | |
| CN104189643A (en) | Osteopathia rehabilitation pill for treating chronic osteomyelitis | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN103285203A (en) | Traditional Chinese medicine composition for preventing and treating bone fracture and preparation method thereof | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN102579607B (en) | Chinese medicine composition for treating acne | |
| CN102228576B (en) | Chinese patent medicine for treating discoid lupus erythematosus | |
| CN104288673A (en) | Traditional Chinese medicine tablet for treating osteoarthritis and preparation method of traditional Chinese medicine tablet | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN105169279A (en) | Traditional Chinese medicine composition for treating knee joint bone hyperplasia | |
| CN104721313A (en) | Nursing medicine for treating acute waist injury | |
| CN105031505A (en) | Medicine for treating benign prostatic hyperplasia hypertrophy and preparation method thereof | |
| CN104740130A (en) | Pharmaceutical composition for treating chronic nephritis | |
| CN102274472A (en) | Traditional Chinese medicine patch for treating female dysmenorrhoea and preparation thereof | |
| CN101869629B (en) | Traditional Chinese medicine for treating renal calculus | |
| CN106310019A (en) | Traditional Chinese medicine composition for treating consumptive lung disease and preparation method thereof | |
| CN105381410A (en) | Traditional Chinese medicinal preparation for treating hepatitis | |
| CN105998579A (en) | Medicine for treating infertility caused by salpingitis as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150701 |